Back to search results

Safety of Baricitinib for Job Syndrome with Lupus-Like Disease or Atopic Dermatitis

This study is testing the safety of a drug called baricitinib in people with Job syndrome (Hyper IgE Syndrome from STAT3 Mutation) who also have lupus-like disease or atopic dermatitis (a type of skin rash). Job syndrome is a genetic immune system disorder that can cause infections and other problems. Baricitinib is already approved for other immune conditions, and researchers want to see if it can help manage symptoms in people with Job syndrome. The main goal is to see how safe baricitinib is and if people can tolerate it. The study plans to enroll 20 participants aged 12 and older who have a confirmed STAT3 gene change causing Job syndrome and are already part of a specific NIH research protocol.

Study design
This is an open-label (everyone knows what treatment they are getting), dose-titration (the dose may change), pilot study involving 20 participants.
What's involved
You would have 5 clinic visits, 4 remote visits, and 2 phone visits over 9 months. You would take baricitinib for 180 days, starting at a lower dose and potentially increasing.
Compensation
Not stated in the trial record.
Follow-up
Safety will be measured through the end of the study, but the exact duration of follow-up after treatment is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07262983

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

Recruiting
PHASE1Ages 12+InterventionalTreatment
National Institute of Allergy and Infectious Diseases (NIAID)
~20 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:baricitinib

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of SAEs, AEs requiring study drug discontinuation.
Measured over Through end of study

Conditions

Hyper IgE Syndrome From STAT3 Mutation
Job s Syndrome
HIES
Lupus
Atopic Dermatitis

Explore related trials

Atopic DermatitisLupus ErythematosusSTAT3 DeficiencySTAT3 Gene

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Alexandra F Freeman, M.D. · PRINCIPAL_INVESTIGATOR · National Institute of Allergy and Infectious Diseases (NIAID)

Who to contact

Alexandra F Freeman, M.D.
[email protected]
(301) 594-9045
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Intrauterine device (IUD)
Bilateral tubal ligation
Abstinence
Vasectomized partner
Hormonal contraception used in combination with barrier method: progestogen containing (oral, intravaginal, transdermal) or progestogen-only (oral, injectable, implantable) starting 30 days prior to initiation of baricitinib

What this trial measures

  • Incidence of SAEs, AEs requiring study drug discontinuation.Through end of study

    To determine the safety and tolerability of JAK inhibitor treatment (baricitinib) in patients with Job s syndrome with lupus-like disease and/or AD.